Edwards Lifesciences Corporation

NYSE:EW

Medical - Devices

Healthcare
$105.23 +0.57%

+$0.49 today

Market cap
$60.51B
Beta
0.87
P/E (TTM)
46.2
EPS (TTM)
$1.89
52W Low $72.30High $89.60

Volume 3.92M

Average 5.02M

EW Income Before Tax

Profit after all operating and non-operating items but before income tax.

Edwards Lifesciences CorporationNYSE: EW

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax growth accelerates

Q2 FY2026 income before tax of $519.8M rose 29.9% year over year, ahead of the -12.9% change in trailing-twelve-month income before tax. Sequentially, it rose 13.2% from the prior quarter. Over 3 fiscal years it compounded at -10.4% a year.

Context

  • Income before tax amounted to 21.0% of revenue in FY2025, down 7.5 pp from a year earlier.
  • Income before tax increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +29.9% holds above the trailing-twelve-month pace of -12.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$519.8M+13.2% QoQ
Last fiscal yearDec 2025
$1.27B-17.8% YoY
LTMJun 2026
$1.42B-12.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.9%——
1 year-17.8%——
3-year CAGR-10.4%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
1.27B USD
Year-over-year change
-17.8%
4-year CAGR
-7.0%

Income Before Tax vs competitors

How EW compares with its peers on the latest reported figures

  • EW's LTM Jun 2026 income before tax of $1.42B is the 2nd highest of the 6 companies compared; the peer median is $119.59M.
  • Its year-over-year change of -12.9% is the 5th highest of 6, against a peer median of +17.6%.
  • Income before tax amounts to 21.8% of revenue for EW, versus a peer median of 13.5%.
EW Competitors Peer median
Income Before Tax for EW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ISRGIntuitive Surgical, Inc.LTM Sep 2026$3.62B +14.3%+27.3%31.3%
EWEdwards Lifesciences CorporationLTM Jun 2026$1.42B -12.9%-10.4%21.8%
PENPenumbra, Inc.LTM Jun 2026$203.83M +17.6%+274.9%13.5%
LIVNLivaNova PLCLTM Sep 2026$119.59M +162.3%—7.9%
AORTArtivion, Inc.LTM Mar 2026$17.41M +177.1%—3.8%
AVRAnteris Technologies Global Corp.LTM Mar 2026-$94.7M -15.8%—5116.2%
Peer median (excluding EW) $119.59M+17.6%+151.1%13.5%

Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.23B5.38B5.01B5.44B6.07B
Cost of Revenue1.23B1.17B1.04B1.12B1.33B
Gross Profit4.01B4.22B3.97B4.32B4.74B
Gross Margin76.6%78.3%79.3%79.5%78.1%
Research & Development903.1M945.2M962.9M1.05B1.08B
Selling, General & Admin1.49B1.57B1.58B1.79B2.09B
Operating Expenses2.4B2.51B2.55B2.94B3.1B
Depreciation & Amortization134.8M139.6M144.9M155.2M156.6M
EBITDA1.86B1.93B1.53B1.72B1.43B
EBITDA Margin35.6%35.9%30.6%31.7%23.6%
Operating Income1.61B1.7B1.43B1.38B1.64B
Operating Margin30.8%31.6%28.5%25.3%27.0%
Interest Income17.4M35.5M67.2M120.3M148.4M
Interest Expense24.8M26.2M17.6M19.8M0
Other Income / Expenses91.6M65M(54.9M)169.4M(363.3M)
Income Before Tax1.7B1.77B1.37B1.55B1.27B
Pre-Tax Margin32.5%32.8%27.4%28.5%21.0%
Income Tax Expense198.9M245.5M152.4M152.1M216.9M
Net Income1.5B1.52B1.4B4.17B1.07B
Net Margin28.7%28.3%28.0%76.7%17.7%
EPS (Basic)2.412.462.316.981.84
EPS (Diluted)2.382.442.306.971.83
Weighted Avg Shares623.3M619M606.7M597.7M584.8M
Weighted Avg Shares (Diluted)631.2M624.2M609.4M599.3M585.8M

Edwards Lifesciences Corporation

NYSE:EW

Intrinsic Alpha fair value

Locked

Current Price

$105.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.